What if computer screens had glasses instead of the people staring at the monitors? That concept is not too far afield from technology being developed by UC Berkeley computer and vision scientists.
Uncategorized
FDA allows open access to adverse drug reaction database
The FDA announced it is making access to its adverse drug reaction reports easier to obtain, with open access to the public. In a press release, Taha Kass-Hout, MD, MS, chief health informatics officer at FDA, said that the information previously diffi…
Vittamed’s Non-Invasive Intracranial Pressure and Cerebrovascular Autoregulation Monitors Cleared in EU (VIDEOS)
Vittamed out of Carlisle, MA received European CE Mark approval for its non-invasive intracranial pressure meter and non-invasive cerebrovascular autoregulation monitor. The Vittamed 205 intracranial pressure monitor works by applying pressure to the tissue surrounding the eye using a special pressure cuff. A Doppler ultrasound transducer plac (Read more...)
Uncategorized
Hyperopic LASIK with low-energy femtosecond laser yields few complications
A low-energy femtosecond laser enabled predictable flap creation and a low retreatment rate for hyperopic LASIK with non-custom ablation, according to a study.The prospective case series study included 800 eyes of 413 patients who underwent hyperopic L…
Uncategorized
FDA announces closer scrutiny of lab-developed tests, companion diagnostics
In an effort to validate the accuracy, consistency and reliability of diagnostic testing, the FDA has announced its intent to issue a final guidance document on the development, review and approval of companion diagnostics. The agency has also alerted Congress that it will publish a risk-based oversight framework for laboratory-developed tests, according to an agency press release. “Ensuring that doctors and patients have access to safe, accurate and reliable diagnostic tests to help guide treatment decisions is a priority for the FDA,” FDA commissioner Margaret A. Hamburg, MD, said in (Read more...)
FDA Green Lights Eylea for DME
(MedPage Today) — The FDA has approved the vascular endothelial growth factor inhibitor aflibercept (Eylea) for diabetic macular edema, drugmaker Regeneron announced.